mor202

mAbexperimental

Clinical trial activity

11 trials · 11 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
9
Phase 3
3
Phase 4
0

Earliest trial started Oct 15, 2019 (NCT04145440)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07219043Phase 2Dec 1, 2025Biogen
NCT06962800Phase 3May 22, 2025Biogen
NCT06935357Phase 3May 8, 2025Biogen
NCT06685757Phase 3Nov 30, 2024Biogen
NCT06064929Phase 1Oct 31, 2023HI-Bio
NCT05140824Phase 1Dec 31, 2021I-Mab Biopharma
NCT05021484Phase 2Oct 31, 2021Humboldt University, Medical University of Vienna, MorphoSys, University of Alberta
NCT04893096Phase 2Oct 31, 2021Mario Negri Institute, MorphoSys
NCT05065970Phase 2Aug 31, 2021MorphoSys
NCT04733040Phase 2Jan 20, 2021MorphoSys
NCT04145440Phase 1/Phase 2 (Phase 2)Oct 15, 2019IQVIA, Metronomia Clinical Research GMBH, MorphoSys, Q2 solutions
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (11)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MorphoSysFor profit5312019
BiogenFor profit4422024
HI-BioFor profit1112023
Humboldt UniversityAcademic/Hospital1012021
I-Mab BiopharmaFor profit1112021
IQVIAFor profit1012019
Mario Negri InstituteAcademic/Hospital1112021
Medical University of ViennaAcademic/Hospital1112021
Metronomia Clinical Research GMBHFor profit1012019
Q2 solutionsFor profit1012019
University of AlbertaAcademic/Hospital1012021
11 organizations
Page 1 / 1